At the 2012 CASSS 9th Symposium on the Practical Applications
of Mass Spectrometry in the Biotechnology Industry, Bruker today
launches the first software solution to encompass the complete
biopharmaceutical characterization challenge, including glycoforms,
impurities and modifications. The unique BioPharmaCompass 1.1
software allows biotech customers to leverage Bruker's leadership in
cutting-edge mass spectrometry for intact protein and post-translational
modification analysis in a routine industrial biologics environment.
BioPharmaCompass 1.1 introduces several major enabling
innovations in the quest for a complete picture of biological products
for regulatory approval and compliance:
-
Intact precise-mass product confirmation and impurity identification
in a single run
-
Handling of multiple-point time-course studies including impurity
analysis and stress studies
-
Antibody determination by top-down sequencing, including antibody-drug
conjugate analysis with instant visualization of N and C terminal
modification analysis against expected batch standard
-
Glycan profiling, PTM and artifact determination, localization and
quantification including novel ETD (electron transfer dissociation)
strategy for determination of deamidation sites
-
Rapid identity testing by peptide mass fingerprinting using digest
match chromatogram search, as well as full software enablement of
combined CID and ETD strategies for 100% sequence coverage even
including formerly difficult-to-sequence domains
-
Automatic combination of data from multiple enzymatic approaches
-
The industry's first automated glycan profiling and identification
workflow, expandable using Bruker's recently launched Glycoquesttm
complete glycoprotein analysis solution and integrated library, making
sophisticated glycoprotein identification and assignment as simple as
a standard protein database search, combining protein sequence and
glyco-structure sequencing data into a single 360 degree report
Bruker has pioneered the field of novel mass spectrometry techniques for
the direct measurement and sequencing of intact proteins. The
industry-leading highest resolution maXis ESI-QqTOF
spectra available at maximum sensitivity for trace impurities, patented
top-down ISD-T3 sequencing on Flex series MALDI TOF/TOF
and best-in-class amazon ETD ion-trap technology for PTM
analysis are all critical steps in a complete understanding of the
composition of a biotherapeutic. Now, BioPharmaCompass 1.1 enables
biotech and pharmaceutical customers to manage information from any or
all of these unique capabilities, dramatically speeding the licensing
and production of biological drugs.